Advertisement
MDT vs TMO
Which Stock Would AI Choose? Medtronic (MDT) vs. Thermo Fisher Scientific (TMO) Stock Comparison
Key Takeaways
- MDT is trading near 52-week lows amid anticipation of fiscal Q4 earnings on June 3, 2026, with analysts projecting modest revenue growth offset by EPS pressure.
- TMO reported Q1 2026 results that beat estimates and recently outlined a long-term 7% organic revenue growth target at its Investor Day.
- MDT operates in medical devices with exposure to cardiovascular, diabetes, and surgical markets, while TMO focuses on life sciences tools, diagnostics, and biopharma services.
- Recent market activity shows TMO exhibiting stronger price momentum compared with MDT’s more pronounced declines.
- Both companies maintain solid balance sheets, but sector positioning and near-term catalysts differ significantly.
- Market sentiment appears more constructive toward TMO following recent corporate updates.
Introduction
Medtronic (MDT) and Thermo Fisher Scientific (TMO) represent two distinct segments within the healthcare sector: medical devices and life sciences instrumentation, respectively. Investors and traders seeking exposure to healthcare innovation, earnings momentum, or relative value opportunities often examine such pairings to assess diversification, growth profiles, and risk-adjusted returns. This comparison highlights observable differences in business models, recent price behavior, and market positioning that may inform portfolio decisions in the current environment.
MDT Overview and Recent Performance
Medtronic is a global leader in medical devices, offering products across cardiovascular, diabetes, and surgical technologies. In recent weeks, the stock has experienced downward pressure, closing at $73.81 on May 29, 2026, near the lower end of its 52-week range. Market activity reflects caution ahead of the company’s fiscal Q4 2026 earnings release scheduled for June 3, with consensus estimates pointing to revenue growth of approximately 8.3% but an EPS decline of about 4.9%. Sentiment has been influenced by broader sector rotation and pre-earnings positioning, with the shares trading below key moving averages.
TMO Overview and Recent Performance
Thermo Fisher Scientific provides life sciences solutions, analytical instruments, and clinical diagnostics, serving biopharma, academic, and healthcare customers. Recent market activity has been more favorable, with the stock closing at $492.51 on May 29, 2026, after a positive response to its May Investor Day and Q1 results. The company reported first-quarter revenue of $11.01 billion, up 6%, and raised its long-term organic growth target to 7% annually. Price momentum improved notably in the latter part of May, supported by capital return initiatives and acquisition activity.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of high-performing AI trading bots from a broader pool of hundreds available across thousands of tickers. Only the most suitable strategies for prevailing market conditions earn placement in this trending section. The platform currently highlights 25 AI trading bots selected from 351 total options, each employing distinct trading styles, timeframes, performance metrics, and ticker sets. These bots range across technical and fundamental approaches and volatility profiles. For traders interested in automated strategies, the page offers a data-driven starting point to explore copy-trading opportunities aligned with current conditions.
Head-to-Head Comparison
Medtronic’s device-centric model exposes it to procedure volumes and regulatory pathways, while Thermo Fisher benefits from recurring revenue in research and diagnostics. Recent momentum favors TMO, which posted better relative price performance following its corporate updates. Risk factors for MDT include upcoming earnings variability and sector headwinds, whereas TMO faces sensitivity to biotech funding cycles. Sector exposure differs: MDT is more procedure-driven, while TMO is tied to laboratory and pharmaceutical spending. Market sentiment has shifted more positively toward TMO in recent weeks based on forward guidance and capital allocation.
Tickeron AI Verdict
Based on observable factors such as recent trend consistency, earnings visibility, and relative positioning, Tickeron’s AI would currently assign a higher probability of outperformance to TMO over the near term. The company’s clearer growth catalysts and stronger price momentum in recent market activity support this probabilistic assessment, though outcomes remain subject to broader market conditions and execution.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDT is a Hold and TMO is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MDT’s FA Score shows that 1 FA rating(s) are green whileTMO’s FA Score has 1 green FA rating(s).
- MDT’s FA Score: 1 green, 4 red.
- TMO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MDT’s TA Score shows that 5 TA indicator(s) are bullish while TMO’s TA Score has 2 bullish TA indicator(s).
- MDT’s TA Score: 5 bullish, 5 bearish.
- TMO’s TA Score: 2 bullish, 8 bearish.
Price Growth
MDT (@Medical/Nursing Services) experienced а -1.38% price change this week, while TMO (@Medical Specialties) price change was -2.05% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -0.01%. For the same industry, the average monthly price growth was -3.66%, and the average quarterly price growth was -16.13%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.73%. For the same industry, the average monthly price growth was +2.80%, and the average quarterly price growth was -3.08%.
Reported Earning Dates
MDT is expected to report earnings on Aug 25, 2026.
TMO is expected to report earnings on Jul 29, 2026.
Industries' Descriptions
@Medical/Nursing Services (-0.01% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (+0.73% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| MDT | TMO | MDT / TMO | |
| Capitalization | 101B | 172B | 59% |
| EBITDA | 9.36B | 11.7B | 80% |
| Gain YTD | -16.805 | -19.763 | 85% |
| P/E Ratio | 21.25 | 25.51 | 83% |
| Revenue | 35.5B | 45.2B | 79% |
| Total Cash | 8.38B | 1.12B | 749% |
| Total Debt | 28.1B | 43.2B | 65% |
MDT | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 12 | 71 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 3 Undervalued | 13 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 97 | |
SMR RATING 1..100 | 74 | 62 | |
PRICE GROWTH RATING 1..100 | 61 | 55 | |
P/E GROWTH RATING 1..100 | 62 | 43 | |
SEASONALITY SCORE 1..100 | 50 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MDT's Valuation (3) in the Medical Specialties industry is in the same range as TMO (13). This means that MDT’s stock grew similarly to TMO’s over the last 12 months.
TMO's Profit vs Risk Rating (97) in the Medical Specialties industry is in the same range as MDT (100). This means that TMO’s stock grew similarly to MDT’s over the last 12 months.
TMO's SMR Rating (62) in the Medical Specialties industry is in the same range as MDT (74). This means that TMO’s stock grew similarly to MDT’s over the last 12 months.
TMO's Price Growth Rating (55) in the Medical Specialties industry is in the same range as MDT (61). This means that TMO’s stock grew similarly to MDT’s over the last 12 months.
TMO's P/E Growth Rating (43) in the Medical Specialties industry is in the same range as MDT (62). This means that TMO’s stock grew similarly to MDT’s over the last 12 months.
| MDT | TMO | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 63% | 2 days ago 47% |
| Stochastic ODDS (%) | 2 days ago 52% | 2 days ago 62% |
| Momentum ODDS (%) | 2 days ago 56% | 2 days ago 53% |
| MACD ODDS (%) | 2 days ago 49% | 2 days ago 51% |
| TrendWeek ODDS (%) | 2 days ago 56% | 2 days ago 61% |
| TrendMonth ODDS (%) | 2 days ago 45% | 2 days ago 61% |
| Advances ODDS (%) | 8 days ago 51% | 23 days ago 62% |
| Declines ODDS (%) | 16 days ago 58% | 12 days ago 63% |
| BollingerBands ODDS (%) | 2 days ago 63% | 2 days ago 60% |
| Aroon ODDS (%) | 2 days ago 55% | 2 days ago 56% |
Advertisement
MDT and
Correlation & Price change
A.I.dvisor indicates that over the last year, MDT has been loosely correlated with SYK. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if MDT jumps, then SYK could also see price increases.
TMO and
Correlation & Price change
A.I.dvisor indicates that over the last year, TMO has been closely correlated with A. These tickers have moved in lockstep 80% of the time. This A.I.-generated data suggests there is a high statistical probability that if TMO jumps, then A could also see price increases.